has been cited by the following article(s):
|
[1]
|
Atropisomerism transforming
anti‐cancer
drug discovery
Chemical Biology & Drug Design,
2023
DOI:10.1111/cbdd.14155
|
|
|
|
|
[2]
|
Atropisomerism transforming
anti‐cancer
drug discovery
Chemical Biology & Drug Design,
2023
DOI:10.1111/cbdd.14155
|
|
|
|
|
[3]
|
High-Level Data Fusion Enables the Chemoinformatically Guided Discovery of Chiral Disulfonimide Catalysts for Atropselective Iodination of 2-Amino-6-arylpyridines
Journal of the American Chemical Society,
2022
DOI:10.1021/jacs.2c08820
|
|
|
|
|
[4]
|
BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe
Journal of Medicinal Chemistry,
2022
DOI:10.1021/acs.jmedchem.2c00441
|
|
|
|
|
[5]
|
High-Level Data Fusion Enables the Chemoinformatically Guided Discovery of Chiral Disulfonimide Catalysts for Atropselective Iodination of 2-Amino-6-arylpyridines
Journal of the American Chemical Society,
2022
DOI:10.1021/jacs.2c08820
|
|
|
|
|
[6]
|
Atropisomerism transforming
anti‐cancer
drug discovery
Chemical Biology & Drug Design,
2022
DOI:10.1111/cbdd.14155
|
|
|
|
|
[7]
|
BAY-069, a Novel (Trifluoromethyl)pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe
Journal of Medicinal Chemistry,
2022
DOI:10.1021/acs.jmedchem.2c00441
|
|
|
|